Definium Therapeutics reports positive Phase 3 topline for DT120 ODT
Definium Therapeutics announced positive topline results from its Phase 3 Panorama study of DT120 ODT for generalized anxiety disorder.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
4 results loaded, newest first. End of these results.
Definium Therapeutics Reports Positive Phase 3 Results
Definium Therapeutics announces positive topline results from Phase 3 Voyage Study of DT120 ODT
Definium Therapeutics Reports Positive Phase 3 Results
Definium Therapeutics announces positive topline results from Phase 3 Voyage Study of DT120 ODT
DFTX Reports Positive Phase 3 Results
Definium Therapeutics announces positive topline results from Phase 3 Emerge Study of DT120 Orally Disintegrating Tablet in Major Depressive Disorder